Loading...
Loading...
First Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics, Inc.. Spoken Alpha tracks TRAXV's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks TRAXV's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TRAXV.
curl https://api.spokenalpha.com/v1/companies/TRAXV| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.25 | $3.34 | +27.1% | +3.3% | +3.8% |
| Q4 FY2026 | $4.29 | $3.37 | +27.2% | -4.4% | -6.8% |
| Q3 FY2026 | $3.95 | $3.28 | +20.5% | -0.2% | +1.1% |
| Q2 FY2026 | $4.39 | $3.54 | +24.0% | -4.0% | -1.8% |
| Q1 FY2025 | $3.99 | $3.53 | +13.1% | -2.7% | -5.3% |
| Q4 FY2025 | $4.44 | $3.45 | +28.8% | +2.1% | +4.6% |
| Q3 FY2025 | $4.30 | $3.47 | +23.8% | +4.4% | +5.4% |
| Q2 FY2025 | $4.04 | $3.55 | +13.9% | +3.2% | +3.4% |
| Q1 FY2024 | $4.18 | $3.39 | +23.4% | +3.8% | +1.5% |
| Q4 FY2024 | $4.58 | $3.58 | +28.0% | -0.8% | +0.9% |